GlassScriptPhysician profile
Jamie Keene
NPI 1184888661
$2,208.86
in general payments reported to CMS, 2019-2025
28 companies · $465 in 2025
The $465 reported for 2025 was more than what 85% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $306 · 2022: $369 · 2023: $674 · 2024: $394 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,448 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,448.34 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $403.13 | 2021-2025 | |
| Astellas Pharma US INC | $303.87 | 2023-2025 | Veozah |
| Pfizer INC. | $185.23 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $145.91 | 2023-2025 | |
| Agile Therapeutics, INC. | $145.88 | 2021-2024 | Twirla |
| Organon LLC | $125.28 | 2021-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $109.77 | 2023-2024 | Myfembree |
| Mylan Pharmaceuticals INC. | $83.31 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.32 | 2021-2025 | |
| Exeltis, USA INC. | $75.06 | 2022-2025 | Slynd |
| Coopersurgical, INC. | $58.54 | 2021-2024 | Paragard T 380a, Paragard T 380a |
| Millicent US INC | $46.45 | 2025 | Femlyv, Intrarosa |
| Therapeuticsmd, INC. | $44.74 | 2021-2022 | |
| Myovant Sciences INC. | $44.47 | 2022 | |
| Exact Sciences Corporation | $39.02 | 2024-2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $38.04 | 2022 | |
| Hologic Sales and Service, LLC | $37.35 | 2024-2025 | Myosure Tissue Removal Device, Fluent Fluid Management System |
| Becton, Dickinson and Company | $28.87 | 2024 | Bd Onclarity |
| Evofem Biosciences, INC. | $28.79 | 2022 | |
| Genzyme Corporation | $27.98 | 2025 | |
| Amgen INC. | $27.97 | 2022-2025 | Evenity |
| Dexcom, INC. | $26.94 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $21.31 | 2025 | |
| Ascend Therapeutics US, LLC | $19.30 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.76 | 2025 | Vpriv |
| Merck Sharp & Dohme LLC | $14.66 | 2021 | |
| Smith+Nephew, INC. | $14.25 | 2023 | Renasys Touch, Pico |
| Avion Pharmaceuticals | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Keene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.